MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

4.12 4.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.9699999999999998

Max

4.17

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+270.45% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	345K 229M
Iepriekšējā atvēršanas cena	0.08
Iepriekšējā slēgšanas cena	4.12

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. apr. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026. g. 17. apr. 18:15 UTC

Galvenie ziņu notikumi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026. g. 17. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026. g. 17. apr. 19:34 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 17. apr. 19:34 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026. g. 17. apr. 19:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026. g. 17. apr. 19:26 UTC

Tirgus saruna

U.S. Natural Gas Futures Edge Up -- Market Talk

2026. g. 17. apr. 19:21 UTC

Tirgus saruna

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026. g. 17. apr. 19:15 UTC

Tirgus saruna

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026. g. 17. apr. 19:07 UTC

Tirgus saruna

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026. g. 17. apr. 18:57 UTC

Galvenie ziņu notikumi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB 2026 Rev Guidance Unchanged

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026. g. 17. apr. 18:14 UTC

Tirgus saruna

Galvenie ziņu notikumi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026. g. 17. apr. 17:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026. g. 17. apr. 17:26 UTC

Tirgus saruna

Peļņas

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

270.45% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 270.45%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.